Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Total Current Liabilities (2017 - 2025)

Entera Bio has reported Total Current Liabilities over the past 9 years, most recently at $2.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 87.33% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 87.33%, and an annual FY2025 reading of $2.2 million, up 87.33% over the prior year.
  • Total Current Liabilities came in at $2.2 million for Q4 2025, up from $1.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $10.6 million in Q1 2021 to a low of $1.1 million in Q4 2023.
  • Median Total Current Liabilities over the past 5 years was $1.7 million (2022), compared with a mean of $2.2 million.
  • The sharpest move saw Total Current Liabilities soared 113.82% in 2021, then crashed 78.01% in 2022.
  • Over 5 years, Total Current Liabilities stood at $3.2 million in 2021, then crashed by 57.58% to $1.3 million in 2022, then fell by 18.64% to $1.1 million in 2023, then rose by 7.79% to $1.2 million in 2024, then soared by 87.33% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Total Current Liabilities are $2.2 million (Q4 2025), $1.6 million (Q3 2025), and $1.8 million (Q2 2025).